Supporting this hypothesis, a study showed an association between treatment with bevacizumab (an anti-VEGF agent used for the treatment of advanced stage of ROP) and neurodevelopmental delay in those infants (46), because of VEGF levels reduction in the retina and the brain as well. This evidence concerns the gene VEGFA and retinopathy of prematurity.